Histone Deacetylase Inhibitors Market Size, Share and Global Trend By Class (Class I HDACs, Class II HDACS, Class III HDACs, Class IV HDACs), Application (Oncology, Neurology), End User (Hospitals, Academic & research institutes, Pharmaceutical companies) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Histone deacetylase inhibitor (HDACI) is an enzyme, which inhibits histone deacetylase by removing the acetyl group from n-acetyl lysine amino acid sequence. Histone deacetylase inhibitors have potential applications in diagnosis, treatment and prognosis of cancer. They are also used as a treatment option for haematological malignancies and play important role in epigenetic or non-epigenetic regulation. In March 2017, AMO PHARMA and Ranedis Pharmaceuticals entered into collaboration to develop RND-001, a histone deacetylase inhibitor used in specific lysosomal storage disorders and neurodegenerative disorders. Recent findings by the researchers suggest that, histone deacetylase inhibitors can be used for the potential multimodal treatment of cachexia.
To gain extensive insights into the market, Request for Customization
Anti-inflammatory and anti-apoptotic properties of histone deacetylase inhibitors can be applied for the treatment of a range of neurological disorders, including multiple sclerosis. Increasing incidence of cancer and neurological disorders, and increasing use of the histone deacetylase inhibitors for the treatment of the disorders related to central nervous system is one of the major factor driving the growth of the global histone deacetylase inhibitors market. Additionally, high investment in the research and development of the cancer treatment, and increased number of collaborations and investments in the histone deacetylase inhibitors manufacturing are some of the factors driving the growth of the global histone deacetylase inhibitors market.
The factor that is expected to inhibit the growth of the market is the lack of favourable reimbursement policies and stringent regulations for the product approval.
Key Players Covered
Some of the major companies that are present in the global histone deacetylase inhibitors market Merck KGaA, Medivir AB, Cetya Therapeutics, BioVision Inc., R&D Systems, Inc., Mirati Therapeutics, Abcam plc., TCI Chemicals (India) Pvt. Ltd., InvivoGen, and other players.
SEGMENTATION
SEGMENTATION | DETAILS |
By Class | · Class I HDACs · Class II HDACS · Class III HDACs · Class IV HDACs. |
By Application | · Oncology · Neurology · Others. |
By End User | · Hospitals, · Academic & research institutes · Pharmaceutical companies · Others. |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
At present, cancer accounts for the largest proportion of the market, this is expected to have higher demand in the field of oncology during the forecast period.
Key Insights
- Prevalence of Key Disease Conditions (Cancer, Haematology Diseases, etc.)
- Pipeline Analysis, Key Players
Regional Analysis
Among these regions, North America dominated the global histone deacetylase inhibitors market in 2017. Development of new drugs, rise in prevalence of cancer and neurological disorders, and high acceptance of histone deacetylase inhibitors are expected to drive the market in the region. According to the American Cancer Society, an estimated 12.0% of U.S. women develop breast cancer in their lifetime. Also, in 2015, about 2,300 men in the U.S., were diagnosed with breast cancer. Europe and Asia Pacific are anticipated to have a significant CAGR during the forecast period, due to rise in number of neurological disorder cases, rise in demand for advanced treatment by the patient pool, and rising healthcare expenditure in the region.
Key Industry Developments
- Huya Bioscience International is currently developing HBI-8000, oral class I selective HDACI.
- In December 2018, Helsinn Healthcare SA., announced interim data of Phase 2 study evaluating pracinostat, a histone deacetylase inhibitor, in combination with azacitadine for the treatment of patients with IPSS-R high/very high-risk of Myelodysplastic Syndrome (MDS).
- A research published by the Graduate Institute of Cancer Biology and Drug Discovery Taipei Medical University, Taipei, Taiwan in 2017, signified the novel class IIa-Selective Histone Deacetylase Inhibitors were discovered using an in silico virtual screening approach.
- In December 2013, Spectrum Pharmaceuticals, Inc., announced submission of new drug application for Belinostat, a novel pan-HDAC inhibitor.
- Ongoing
- 2023
- 2019-2022
Personalize this Research
- Granular Research on Specified Regions or Segments
- Companies Profiled based on User Requirement
- Broader Insights Pertaining to a Specific Segment or Region
- Breaking Down Competitive Landscape as per Your Requirement
- Other Specific Requirement on Customization
Healthcare Clients
